Mark is Chair and Chief Executive Officer of Kala Bio. Mark currently serves on the boards of Nimbus, Aerovate Therapeutics, Akero Therapeutics, Third Harmonic Bio, Q32 Bio and Merus. He previously served as President and Chief Executive Officer of Civitas Therapeutics and Sunovion Pharmaceuticals Inc. Earlier in his career he was Vice President and Business Unit Head at Novartis Pharmaceuticals Corporation and held management positions at Astra Merck Inc. and Merck & Co. He previously served on the board of Aimmune Therapeutics. Mark holds a B.S. in Business Administration from Ball State University and an M.B.A. from Loyola University.